Jenburkt PharmaceuticalsBOM:524731 -1.47%81 EBITDA Margin % is 32.82% as of Mar. 2026, which is 32% above its 10-year median of 24.80. GuruFocus rates BOM:524731 with a GF Score™ of 81/100 and a GF Value™ of ₹1,111.70 (Fairly Valued). The stock has 1 warning sign investors should review. Among 953 Drug Manufacturers companies, Jenburkt Pharmaceuticals ranks better than 85.73% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Jenburkt Pharmaceuticals EBITDA Margin % Related Terms
Jenburkt Pharmaceuticals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524731 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jenburkt Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jenburkt Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jenburkt Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Jenburkt Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jenburkt Pharmaceuticals (BOM:524731) has a EBITDA Margin % of 32.82% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jenburkt Pharmaceuticals and its competitors. This is 32% above median its historical median of 24.80. Over the past decade, Jenburkt Pharmaceuticals' EBITDA Margin % has ranged from 20.13 to 31.06. According to the industry distribution chart, Jenburkt Pharmaceuticals ranks #136 out of 953 companies in the Drug Manufacturers industry, placing it in the top 14.3%.
Is Jenburkt Pharmaceuticals' EBITDA Margin % too high?
Jenburkt Pharmaceuticals' current EBITDA Margin % of 32.82% is 32% above median its 10-year median of 24.80. Over the past 10 years, this metric has ranged from a low of 20.13 to a high of 31.06. The Drug Manufacturers industry median EBITDA Margin % is 12.54. Jenburkt Pharmaceuticals' value of 32.82% is 161.7% above this industry median. Based on the distribution chart, Jenburkt Pharmaceuticals ranks #136 out of 953 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jenburkt Pharmaceuticals has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jenburkt Pharmaceuticals' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jenburkt Pharmaceuticals ranks #136 out of 953 companies for EBITDA Margin %. This places Jenburkt Pharmaceuticals in the top 14% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.54. Jenburkt Pharmaceuticals' value of 32.82% is 161.7% above this benchmark. Historically, Jenburkt Pharmaceuticals' own EBITDA Margin % has ranged from 20.13 to 31.06 over the past decade. While the company's 10-year median is 24.80 vs. the industry median of 12.54, Jenburkt Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jenburkt Pharmaceuticals's current EBITDA Margin % of 32.82% is 161.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jenburkt Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jenburkt Pharmaceuticals's current EBITDA Margin % is 32.82%, which is 32% above median its own 10-year median of 24.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jenburkt Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jenburkt Pharmaceuticals (BOM:524731) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,111.70, compared to a current price of ₹1,109.65 — trading 0.2% below its estimated fair value. The current EBITDA Margin % is 32.82%, which is 32% above median its 10-year median of 24.80 and 161.7% above the Drug Manufacturers industry median of 12.54. Jenburkt Pharmaceuticals' overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Jenburkt Pharmaceuticals (BOM:524731), the current EBITDA Margin % is 32.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jenburkt Pharmaceuticals (BOM:524731) Overvalued in 2026?
Based on GuruFocus' analysis, Jenburkt Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹1,109.65 is trading 0.2% below its estimated GF Value™ of ₹1,111.70.
GuruFocus considers Jenburkt Pharmaceuticals to be Fairly Valued.
Key valuation signals for BOM:524731:
EBITDA Margin %: 32.82% (32% above median its 10-year median of 24.80)
GF Value™: ₹1,111.70 vs. price of ₹1,109.65 (0.2% below fair value)
Industry Position: 161.7% above the Drug Manufacturers median (#136 of 953)
No single metric tells the full story. See the BOM:524731 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jenburkt Pharmaceuticals Ltd is engaged in the manufacturing, producing, developing, and marketing of pharmaceutical formulations. The company operates in one segment - pharmaceutical formulations. The company generates key revenue from the local market.
81GF Score
Get the complete analysis for BOM:524731
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524731 has been successfully added to your 
